PhRMA floating DTC guidelines draft

Share this article:

A draft of proposed voluntary guidelines for DTC advertising is circulating among Pharmaceutical Research and Manufacturers of America (PhRMA) members. A vote on the principles containted in the draft is expected sometime this summer, said PhRMA communications head Ken Johnson.
"The goal is to make DTC more educational and informational and less promotional," said Johnson.
The draft, written by PhRMA staff, is the latest effort by the group to draw up voluntary guidelines for DTC, a cause championed by former PhRMA chairman and Abbott chief Miles White. Past efforts have foundered amid member disagreement, but the initiative has taken on new urgency since the withdrawal of Vioxx, with DTC under withering scrutiny in Washington.
Current PhRMA chairman Bill Weldon, of Johnson & Johnson, vowed to press the effort in remarks at the group's annual meeting last March. "Several of the companies in this room have adopted guiding principles for direct to consumer advertising and are using them to help educate consumers," Weldon told PhRMA delegates, adding that the best approaches "underscore the right way to use medicines ... better balance information about risks and benefits ... and help consumers understand that all medicines have side effects that are best discussed with one's doctor."

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...